MinervaX Overview

  • Founded
  • 2009
Founded
  • Status
  • Private
  • Latest Deal Type
  • 2ndary - Private
  • Investors
  • 15

MinervaX General Information

Description

Developer of maternal vaccines designed for the prevention of adverse pregnancy outcomes and life-threating infections caused by group B streptococcus. The company's vaccines specializes in the research and development of drugs that utilize a particular fusion protein that elicits protective immunity against a range of clinically relevant streptococci strains, enabling medical professionals to prevent new-born babies from contracting bacterial infections.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
  • Ole Maaløes Vej 3
  • 2200 Copenhagen
  • Denmark

MinervaX Timeline

2018201920202021
Financing Round
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

MinervaX Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
13. Secondary Transaction - Private 01-Apr-2021 000.00 Completed Clinical Trials - Phase 2
12. Later Stage VC (Series B) 15-Dec-2020 000.00 000.00 Completed Clinical Trials - Phase 2
11. Secondary Transaction - Private 000.00 Completed Clinical Trials - Phase 1
10. Later Stage VC 21-Jan-2019 00.000 000.00 Completed Clinical Trials - Phase 1
9. Grant 19-Sep-2016 00.000 00.000 Completed Clinical Trials - Phase 1
8. Later Stage VC 15-Feb-2016 00.000 00.000 Completed Clinical Trials - Phase 1
7. Grant 28-Oct-2015 00000 00.000 Completed Clinical Trials - Phase 1
6. Early Stage VC 08-Jan-2014 00.000 00.000 Completed Clinical Trials - Phase 1
5. Grant 01-Jan-2013 $7.87M Completed Startup
4. Early Stage VC 31-Dec-2011 Completed Startup
To view MinervaX’s complete valuation and funding history, request access »

MinervaX Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of maternal vaccines designed for the prevention of adverse pregnancy outcomes and life-threating infections c
Drug Discovery
Copenhagen, Denmark
000.00
00000000000 000.00

00000000

iat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deseru
0000 000000000
Cantanhede, Portugal
00 As of 0000
00000
00000 00000 00000

00 00000

aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea co
0000 000000000
Copenhagen N, Denmark
00 As of 0000
00000
00000000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

MinervaX Competitors (54)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Immunethep Venture Capital-Backed Cantanhede, Portugal 00 00000 00000 00000 00000
00 0000000 Venture Capital-Backed Copenhagen N, Denmark 00 00000 00000000000 00000
000000000 00000000 Venture Capital-Backed Rockville, MD 0 000.00 0000000000 0 000.00
00000 00000 000000 Venture Capital-Backed Geneva, Switzerland 00 00000 0000000000 0 00000
00000000 Venture Capital-Backed Genève, Switzerland 00 000.00 00000000000 000.00
You’re viewing 5 of 54 competitors. Get the full list »

MinervaX Executive Team (6)

Name Title Board Seat Contact Info
Per Fischer Ph.D Co-Founder and Chief Executive Officer
Bo Henriksen Chief Financial Officer
Bengt Lindbom Ph.D Chief Scientific Officer
Michael Darsley Ph.D Head, Clinical Development
Kim Hejnaes Head, Manufacturing
You’re viewing 5 of 6 executive team members. Get the full list »

MinervaX Board Members (15)

Name Representing Role Since
Bent Østergaard MinervaX Board Member 000 0000
Bita Sehat Ph.D Industrifonden Board Member 000 0000
Christopher Gagliardi Ph.D Sanofi Ventures Board Member 000 0000
Emmanuelle Coutanceau Ph.D Novo Holdings Board Member 000 0000
Kabeer Aziz Adjuvant Capital Board Member 000 0000
You’re viewing 5 of 15 board members. Get the full list »

MinervaX Investors (15)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Adjuvant Capital Impact Investing Minority 000 0000 000000 0
Industrifonden Venture Capital Minority 000 0000 000000 0
Sanofi Ventures Corporate Venture Capital Minority 000 0000 000000 0
Wellington Partners Venture Capital Minority 000 0000 000000 0
Heartcore Capital Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 15 investors. Get the full list »